ArticleJournal of the American Chemical Society2026
Receptor-Mediated Shuttling of a D-Amino Acid Peptide Achieves High Nanomolar Cytosolic Concentrations.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivery of therapeutic peptides and proteins to the cytosol is of great interest due to their ability to inhibit intracellular protein-protein interactions, which are mostly deemed undruggable by small molecules. Internalization into the endosomal pathway is possible by receptor-targeted approaches; however, endosomal escape is inefficient, and its quantification is challenging. To improve our current understanding of cytosolic delivery, we performed comprehensive studies on a receptor-mediated shuttle system based on the chemokine-like receptor 1 (CMKLR1). As a model cargo, PMIγ was used, a known D-amino acid peptide antagonist of the MDM2/p53 interaction, which survives the harsh conditions in the endocytic pathway. Fluorescence correlation spectroscopy (FCS) was used to demonstrate that biologically meaningful cytosolic concentrations (>100 nM) can be reached by receptor-mediated shuttling, even when no endosomal escape enhancing strategies are used. Attachment of the pH-responsive endosomal escape peptide (EEP) hsLMWP further improved cytosolic delivery but also induced cellular toxicity at higher concentrations. Additionally, the EEP activity was likely limited by its fast degradation after internalization. Intracellular biological activity was confirmed using bioluminescence resonance energy transfer (BRET) studies, which demonstrate binding to MDM2 and inhibition of the p53/MDM2 interaction. This study highlights the potential of receptor-mediated shuttling for cytosolic delivery of therapeutic peptides and provides new insights into achievable intracellular concentrations, advancing the field of peptide therapeutics and drug delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.